Cancercompass News: prostate cancerCancerCompass is an online community committed to offering people living with cancer a place to receive cancer information and news, share knowledge, and share cancer treatment experiences. To learn more, visit our site today.Poniard Announces Positive First-line Efficacy And Safety Data From Ongoing Phase 2 Trial Of Picoplatin In Patients With Metastatic Hormone Refractory- June 13, 2008 Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on oncology, today presented preliminary safety and efficacy data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone, the standard of care for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC). Results demonstrated that picoplatin can be safely administered with full doses of docetaxel. In addition, the prostate specific antigen (PSA) response rate...http://www.cancercompass.com/cancer-news/1,14351,00.htm?rss=y Leading Academic Institutions Collaborate On 800-patient Study Of Effectiveness Of Cryoablation For Men With Recurrent Prostate Cancer- June 13, 2008 Endocare, Inc., an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation, announced that a group of the nation's leading academic institutions are collaborating on an 800-patient, multi-center, prospective study of the effectiveness of cryoablation on men whose prostate cancer has recurred after radiation therapy. The study, called SCORE (Salvage Cryotherapy Registry Evaluation) is being led by E. David Crawford, M.D., and Al Barqawi, M.D.,...http://www.cancercompass.com/cancer-news/1,14353,00.htm?rss=y Report Identifies SPINK1 as a New Biomarker for Prostate Cancer- June 10, 2008 ANN ARBOR, Mich. -- Compendia Bioscience, Inc., the leading provider of cancer profiling data and analysis tools, today announced the central role of their flagship product Oncomine(TM) in the discovery and identification of SPINK1 as a key new therapeutic target and biomarker for prostate cancer. Oncomine is a rapidly growing compendium of nearly 26,000 gene expression and DNA copy number arrays coupled with analysis functions and a web application for data mining and visualization. Comprised..http://www.cancercompass.com/cancer-news/1,14335,00.htm?rss=y Prostate Cancer Foundation Grants More Than $19 Million To Cancer Research Programs- June 6, 2008 SANTA MONICA, Calif. -- The Prostate Cancer Foundation (PCF) has committed more than $19 million in new research funding for scientific investigations focused on discovering new treatments for recurrent prostate cancer. A total of eight programs representing 18 leading research institutions and 36 researchers were selected as part of the foundation's 2008 Challenge Awards. The funded programs will receive the first of three annual payments, ranging between $500,000 and $1.0 million per program,.http://www.cancercompass.com/cancer-news/1,14319,00.htm?rss=y No Association Found Between Vitamin D Concentration In Blood And Risk Of Prostate Cancer- June 6, 2008 High vitamin D concentration in the blood is not associated with a reduced risk of prostate cancer, researchers report in an article published online May 27 in the Journal of the National Cancer Institute. Laboratory studies suggested that high doses of vitamin D may reduce the risk of prostate cancer, but epidemiological studies that have examined the relationship have reported inconsistent results. In a nested case-control study, Jiyoung Ahn, Ph.D., and Richard Hayes D.D.S., Ph.D., of the...http://www.cancercompass.com/cancer-news/1,14318,00.htm?rss=y Cryoablation Offers Second Chance For Patients Whose Cancer Returns After Radiation- June 6, 2008 IRVINE, Calif. -- Endocare, Inc., an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation, announced today that a group of the nation's leading academic institutions are collaborating on an 800-patient, multi-center, prospective study of the effectiveness of cryoablation on men whose prostate cancer has recurred after radiation therapy. The study, called SCORE (Salvage Cryotherapy Registry Evaluation) is being led by E. David Crawford, M.D.,..http://www.cancercompass.com/cancer-news/1,14315,00.htm?rss=y Study Offers Hope To Prostate Patients Whose Cancer Returns Following Radiation- June 6, 2008 AURORA, Colo. -- Each year approximately 200,000 men are diagnosed with prostate cancer in the United States and according to estimates from the National Cancer Center Database 29 percent are treated with radiation. Roughly one-third of those treatments will fail. Currently, there are few options for prostate cancer patients whose cancer returns after radiation. Surgery is often considered too invasive and repeating radiation is difficult due to the resistance of the cancer. Now, the University.http://www.cancercompass.com/cancer-news/1,14316,00.htm?rss=y External-Beam Radiation Therapy For Localized Prostate Cancer Linked To Other Cancer- June 6, 2008 Patients undergoing external-beam radiation therapy (EBRT) for localized prostate cancer may be at an increased risk for secondary malignancy, according to a study from researchers in Canada, Italy and the United States presented today during the Annual Scientific Meeting of the American Urological Association (AUA) in Orlando. Researchers presented data to reporters during a special press conference on May 19, 2008 at 1:30 p.m. These findings have significant implications for men evaluating...http://www.cancercompass.com/cancer-news/1,14317,00.htm?rss=y Research Explains How Advanced Prostate Cancer Becomes Resistant To Androgen-Deprivation Therapy- June 3, 2008 SEATTLE -- For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone -- the hormone that fuels prostate-cancer growth -- via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow. A team...http://www.cancercompass.com/cancer-news/1,14288,00.htm?rss=y Apthera's NeuVax Produces Delays In Recurrence In High-risk HER2-positive Prostate Cancer Patients- June 3, 2008 SCOTTSDALE, Ariz. -- NeuVax (E75) produces a delay in disease recurrence in high-risk, disease-free, HER2-positive prostate cancer patients, according to an analysis of the 5-year follow-up data from a Phase III clinical trial. Prostate cancer patients demonstrating various levels of HER2neu expression were treated with NeuVax to determine the ability of the drug to decrease post-prostatectomy prostate-specific antigen (PSA) and clinical recurrences. Data presented at the American Society of...http://www.cancercompass.com/cancer-news/1,14290,00.htm?rss=y |